Changeflow GovPing Pharma & Drug Safety Carbohydrate Binding Module Variants and Hybrid...
Routine Rule Added Final

Carbohydrate Binding Module Variants and Hybrid Polypeptides Comprising Same

Favicon for changeflow.com USPTO Patent Grants - Peptides (C07K)
Published
Detected
Email

Summary

USPTO granted Patent US12600996B2 to Novozymes A/S on April 14, 2026, covering cellobiohydrolase variants and carbohydrate binding module variants. The patent also protects polynucleotides encoding the variants, nucleic acid constructs, vectors, host cells, and associated production methods. The patent contains 33 claims and was filed under application number 17812259.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

USPTO issued Patent US12600996B2 to Novozymes A/S covering carbohydrate binding module variants and hybrid polypeptides. The patent protects cellobiohydrolase variants, polynucleotides encoding them, and methods of using the variants. Filing date was July 13, 2022, under application 17812259, with 33 claims granted.

For competitors in enzyme and biotechnology manufacturing, this patent establishes intellectual property boundaries around carbohydrate binding module technology. Companies developing similar cellobiohydrolase variants or related production methods should review the patent claims to assess potential licensing needs or design-around requirements.

Archived snapshot

Apr 18, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Carbohydrate binding module variants and hybrid polypeptides comprising same

Grant US12600996B2 Kind: B2 Apr 14, 2026

Assignee

Novozymes A/S

Inventors

Peter Westh, Kim Borch, Trine Soerensen, Michael Windahl, Brett McBrayer

Abstract

The present invention relates to cellobiohydrolase variants and carbohydrate binding module variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.

CPC Classifications

C12P 19/14 C12P 5/02 C12P 7/14 C12P 7/16 C12P 7/18 C12P 7/20 C12P 19/02 C12P 2203/00 C12N 9/2437 C12N 15/8257 C12Y 302/01091 C07K 2319/00

Filing Date

2022-07-13

Application No.

17812259

Claims

33

View original document →

Get daily alerts for USPTO Patent Grants - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 14th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12600996B2

Who this affects

Applies to
Pharmaceutical companies Manufacturers Investors
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Patent grant Enzyme technology Biotech IP
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Chemical Manufacturing Pharmaceuticals

Get alerts for this source

We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!